Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congr

[
Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congr
[og_img]
https://www.investing.com/news/press-releases/abbisko-therapeutics-to-present-updated-results-from-the-phase-2-study-of-irpagratinib-in-combination-with-atezolizumab-for-the-treatment-of-advanced-hepatocellular-carcinoma-at-the-2025-esmo-gi-congr-93CH-4040545


Investing.com